Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.– What kind of treatment is Donanemab?

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

A couple from Hull have called on the government to fund new Alzheimer's drugs, even though they say it will come "too late" to help them. Elaine Windass, whose husband, Brian, was diagnosed with Alzheimer's Disease in 2022,

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like him will be able to access treatments. New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease.

A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”. The news comes as the UK’s medicines regulator said donanemab could be licensed for use in the UK.

Donanemab: Alzheimer's 'wonder drug' blocked for use on NHS over cost concerns - Campaigners say decision is ‘frustrating setback’ for people living with disease